Research digest · Delta sleep-inducing peptide · EEG & sleep architecture
DSIP: nine amino acids, one famous EEG signature, and a mechanism still missing after 40 years.
A data-forward digest of the delta sleep-inducing peptide — the numbers the EEG, sleep-architecture, and neuroendocrine studies actually recorded, and the places the evidence stays thin.
The short version
DSIP stands for delta sleep-inducing peptide. It is a tiny natural molecule — a chain of nine amino acids — first pulled from the blood of sleeping rabbits in 1977 and named because, when researchers infused it into the brain, the slow "delta" brain waves of deep sleep got stronger [1]. People in research-use communities try it hoping for deeper, more restful sleep. Here is the honest part: scientists still have not found the receptor it acts on, the gene that makes it, or even a clear, repeatable mechanism. A 2006 review flatly called the sleep evidence "extremely poorly documented and still weak" [3]. Some people who try it report falling asleep more easily; a large share report feeling nothing at all. This site sums up what the studies measured — the real numbers and the real gaps. What people report, including the downsides, is on the effects page.
What the DSIP literature actually measured
Start with the founding number. In 1977, Schoenenberger and Monnier isolated a nonapeptide (a nine-amino-acid chain, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) from the cerebral venous blood of rabbits in electrically induced sleep, and showed that infusing it produced a significant, specific enhancement of delta and spindle EEG activity [1]. That single result — slow brain waves, amplified — is why the molecule carries "delta sleep-inducing" in its name.
The animal EEG numbers reinforce it. In rats, DSIP produced roughly a 35% mean increase in neocortical and limbic delta EEG power, with more frequent theta bursts and changes sustained for up to 11 hours [9]. In cats, 120 nmol/kg given under the skin significantly increased slow-wave sleep without suppressing REM and reduced waking — evidence that peripherally injected DSIP can still reach the central nervous system [10].
The human numbers are smaller and older. In six middle-aged chronic insomniacs, a single intravenous dose of 25 nmol/kg lengthened sleep, cut interruptions, slightly raised REM, and produced no daytime sedation — with the sleep-promoting effect appearing in the second hour after injection, not the first [2]. A later report in severe chronic insomnia described improved sleep efficiency and duration plus significant daytime alertness gains, carrying into the first post-treatment night [7].
DSIP
Beyond sleep, DSIP shows up across the neuroendocrine literature — which is part of why its story is hard to pin down. Intravenous DSIP at 25 nmol/kg in men cut plasma ACTH-like immunoreactivity for at least three hours while leaving cortisol on its normal daily decline [4], pointing at the hypothalamic-pituitary-adrenal (HPA) axis (the body's stress-hormone system). The molecule has also been detected endogenously — in plasma, cerebrospinal fluid, and even milk, usually bound to a carrier protein, and in gut endocrine cells, with the human gut its richest known source [13]. A phosphorylated natural form, DSIP-P, is reported as more potent than the parent peptide in some assays [11]. The catch running through all of it: no DSIP gene, precursor protein, or specific receptor has ever been conclusively identified [3].
What stays unproven
The honest gaps matter as much as the findings. The signature sleep effect has been inconsistently replicated, and a 2006 Journal of Neurochemistry review concluded that synthetic analogs — not native DSIP — often drove the clearest effects, calling the whole picture a "still unresolved riddle" [3]. Cross-species results diverge: rat data show DSIP raising growth hormone through a dopamine pathway, but the human and longevity claims rest on smaller or single-lineage datasets [11][3]. There is no large randomized controlled trial, no validated human pharmacokinetic profile, and no regulatory approval for any use [3]. DSIP is not approved by the FDA or any other regulator; "Emideltide" is its international nonproprietary name, but no Emideltide product has ever been marketed. The full DSIP research record — including the 2024 fusion-peptide work — is laid out study by study, and DSIP for sleep collects the sleep-architecture numbers in one place.